This retrospective baseline study, funded by Johnson and Johnson, collected demographic, clinical, and laboratory indicators on children and adolescents initiated on Darunavir/Etravirine (DRV/ETR) through the New Horizons Collaborative in participating countries to inform future data collection efforts.
Data Collection Period: November 2015-June 2016
Findings published in the Pediatric Infectious Disease Journal, July 2018: “Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment“